Table 2

Patient status after 3 months

Total
(n=2052)
Germany
(n=795)
France
(n=542)
UK
(n=715)
P value
Patients available/lost to FU, n (%)2039/13786/9542/0711/4
AVR planned, n (%)1431 (70.2)686 (87.3)388 (71.6)357 (50.2)<0.001
 AVR performed, n (%)1178 (82.3)624 (91.0)350 (90.2)204 (57.1)<0.001
 TAVI, n (%)847 (71.9)519 (83.2)196 (56.0)132 (64.7)<0.001
 SAVR, n (%)331 (28.1)105 (16.8)154 (44.0)72 (35.3)
 Death despite AVR, n (%)44 (3.7)33 (5.3)7 (2.0)4 (2.0)0.012
 Time to AVR (days)26.0±25.124.9±25.019.5±20.440.3±27.2<0.001
 Time to TAVI (days)24.9±25.622.7±25.118.3±19.943.1±26.9<0.001
 Time to SAVR (days)28.9±23.835.8±21.821.1±20.935.2±27.3<0.001
 AVR not performed, n (%)253 (17.7)62 (9.0)38 (9.8)153 (42.9)<0.001
 Death on waiting list, n (%)12 (0.8)7 (1.0)1 (0.3)4 (1.1)0.311
AVR not planned or no info, n (%)608 (29.8)100 (12.7)154 (28.4)354 (49.8)<0.001
 Death, n (%)59 (9.7)12 (12.0)10 (6.5)37 (10.5)0.267
All-cause death115 (5.6)52 (6.6)18 (3.3)45 (6.3)0.023
 Cardiac-related death (%)53 (2.6)25 (3.2)11 (2.0)17 (2.4)0.393
 Non-cardiac death (%)39 (1.9)15 (1.9)7 (1.3)17 (2.4)0.371
 Unknown cause (%)23 (1.1)12 (1.5)0 (0)11 (1.5)0.015
  • AVR, aortic valve replacement; FU, follow-up; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.